MARC details
| 000 -LEADER |
|---|
| fixed length control field |
12373cam a2200445 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
18425101 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20201021111603.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
141231t20152015njua b 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2014050157 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780470915370 (cloth) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Cancelled/invalid ISBN |
9781118889916 (ePub) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(DNLM)101648918 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DNLM/DLC |
| Transcribing agency |
DLC |
| Description conventions |
rda |
| Modifying agency |
DLC |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RM345 |
| Item number |
.L59 2015 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WG 166 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.1061 |
| Edition number |
23 |
| Item number |
L.Y.C |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Li, Yunbo, |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Cardiovascular diseases : |
| Remainder of title |
from molecular pharmacology to evidence-based therapeutics / |
| Statement of responsibility, etc |
Y. Robert Li, Professor of Pharmacology, Chair of Department of Pharmacology, Campbell University SOM, Buies Creek, North Carolina, USA, Adjunct Professor of Biomedical Engineering and Sciences, Virginia Tech-Wake Forest University, School of Biomedical Engineering and Sciences, Blacksburg, Virginia, USA, Adjunct Professor of Biomedical Sciences and Pathobiology, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA, Adjunct Professor of Biology, Department of Biology, University of North Carolina College of Arts and Sciences, Greensboro, North Carolina, USA. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Hoboken, New Jersey : |
| Name of publisher, distributor, etc |
Wiley, |
| Date of publication, distribution, etc |
[2015] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xxv, 465 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
29 cm |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 500 ## - GENERAL NOTE |
|---|
| General note |
pharmacy bookfair2016 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
UNIT I GENERAL INTRODUCTION 1 1 Introduction to Cardiovascular Diseases 3 1.1 Overview 3 1.2 Definition of Cardiovascular Diseases 3 1.3 Classification of Cardiovascular Diseases 3 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases 5 1.5 Risk Factors of Cardiovascular Diseases 9 1.6 Prevention and Control of Cardiovascular Diseases 10 1.7 Cardiovascular Risk Prediction and Evidence ]Based Treatments 15 1.8 Summary of Chapter Key Points 18 1.9 Self-Assessment Questions 18 References 19 2 Introduction to Principles of Pharmacology 21 2.1 Overview 21 2.2 Definitions and History 21 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology 24 2.4 Principles of Drug Discovery, Development, and Regulation 31 2.5 Pharmacology Subspecialties 32 2.6 Introduction to Cardiovascular Pharmacology 32 2.7 Summary of Chapter Key Points 38 2.8 Self ]Assessment Questions 39 References 40 UNIT II DYSLIPIDEMIAS 43 3 Overview of Dyslipidemias and Drug Therapy 45 3.1 Introduction 45 3.2 Lipoprotein Metabolism 45 3.3 Dyslipidemias and Genetic Lipoprotein Disorders 51 3.4 Mechanistically Based Drug Therapy of Dyslipidemias 51 3.5 Summary of Chapter Key Points 53 3.6 Self ]Assessment Questions 54 References 54 4 Drugs for Dyslipidemias 56 4.1 Overview 56 4.2 Statins 56 4.3 Bile Acid Sequestrants 64 4.4 Cholesterol Absorption Inhibitors 69 4.5 Fibrates 72 4.6 Niacin 75 4.7 New Drugs for HoFH 80 4.8 Phytosterols and Phytostanols 83 4.9 Omega ]3 Fatty Acids 86 4.10 Emerging Therapeutic Modalities for Dyslipidemias 88 4.11 Summary of Chapter Key Points 93 4.12 Self-Assessment Questions 93 References 95 5 Management of Dyslipidemias: Principles and Guidelines 99 5.1 Overview 99 5.2 General Principles of the Management of Dyslipidemias 99 5.3 Current Evidence ]Based Guidelines on the Management of Dyslipidemias 102 5.4 Summary of Chapter Key Points 113 5.5 Self ]Assessment Questions 113 References 114 UNIT III HYPERTENSION AND MULTITASKING CARDIOVASCULAR DRUGS 117 6 Overview of Hypertension and Drug Therapy 119 6.1 Introduction 119 6.2 Definitions, Classifications, and Epidemiology of Hypertension 119 6.3 Pathophysiology of Hypertension 121 6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview 123 6.5 Summary of Chapter Key Points 123 6.6 Self ]Assessment Questions 125 References 125 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
7 Diuretics 127 7.1 Overview 127 7.2 Volume Regulation and Drug Targeting 127 7.3 Thiazide and Thiazide ]Type Diuretics 129 7.4 Loop Diuretics 134 7.5 Potassium ]Sparing Diuretics 138 7.6 Other Diuretics 142 7.7 Summary of Chapter Key Points 143 7.8 Self ]Assessment Questions 143 References 144 8 Sympatholytics 147 8.1 Overview 147 8.2 Sympathetic Nervous System and Drug Targeting 147 8.3 ]Adrenergic Receptor Antagonists 150 8.4 ]Adrenergic Receptor Antagonists 150 8.5 Centrally Acting Sympatholytics 157 8.6 Summary of Chapter Key Points 158 8.7 Self ]Assessment Questions 159 References 159 9 Inhibitors of the Renin Angiotensin Aldosterone System 161 9.1 Overview 161 9.2 The RAAS and Drug Targeting 161 9.3 Direct Renin Inhibitors 162 9.4 ACE Inhibitors 166 9.5 ARBs 174 9.6 Comparative Pharmacology of Direct Renin Inhibitors, ACE Inhibitors, and ARBs 179 9.7 Summary of Chapter Key Points 181 9.8 Self-Assessment Questions 181 References 182 10 Calcium Channel Blockers 185 10.1 Overview 185 10.2 Calcium Channels and Drug Targeting 185 10.3 L-TYPE CCBs 186 10.4 Summary of Chapter Key Points 192 10.5 Self-Assessment Questions 192 References 193 11 Nitrates and Other Vasodilators 194 11.1 Overview 194 11.2 Drug Class and Drug Targeting 194 11.3 Organic Nitrates and Sodium Nitroprusside (Nitric Oxide ]Releasing Vasodilators) 196 11.4 ET Receptor Antagonists 201 11.5 Phosphodiesterase 5 Inhibitors 204 11.6 sGC Stimulators 207 11.7 K+ATP Channel Openers 209 11.8 Other Vasodilators 210 11.9 Summary of Chapter Key Points 212 11.10 Self-Assessment Questions 212 References 213 12 Management of Hypertension: Principles and Guidelines 215 12.1 Overview 215 12.2 Introduction to Current Guidelines for the Management of Systemic Hypertension 215 12.3 Key Recommendations of Major Guidelines for the Management of Systemic Hypertension 217 12.4 Lifestyle Modifications for the Management of Systemic Hypertension 221 12.5 Drug Therapy of Systemic Hypertension 223 12.6 Drug Therapy of Prehypertension 234 12.7 Drug Therapy of Pulmonary Hypertension 235 12.8 Summary of Chapter Key Points 237 12.9 Self-Assessment Questions 238 References 239 UNIT IV ISCHEMIC HEART DISEASE: STABLE ISCHEMIC HEART DISEASE 243 13 Overview of Ischemic Heart Disease, Stable Angina, and Drug Therapy 245 13.1 Introduction 245 13.2 Classification, Epidemiology, and Pathophysiology 245 13.3 Stable Angina and Drug Targeting 250 13.4 Summary of Chapter Key Points 252 13.5 Self-Assessment Questions 252 References 253 14 Drugs for Stable Angina 254 14.1 Overview 254 14.2 -Blockers for Treating Stable Angina 254 14.3 CCBs for Treating Stable Angina 255 14.4 Organic Nitrate for Treating Stable Angina 255 14.5 New Antianginal Drugs: Ranolazine 255 14.6 Other New and Emerging Drugs 258 14.7 Summary of Chapter Key Points 259 14.8 Self-Assessment Questions 259 References 260 15 Management of Stable Angina/Stable Ischemic Heart Disease: Principles and Guidelines 262 15.1 Overview 262 15.2 Introduction to Current Guidelines on Management of Stable Angina/SIHD 262 15.3 General Principles of Management of Stable Angina/SIHD 265 15.4 Current Guideline Recommendations on Stable Angina/SIHD Management 266 15.5 Management of Special Types of Stable Angina 271 15.6 Summary of Chapter Key Points 273 15.7 Self-Assessment Questions 273 References 273 UNIT V ISCHEMIC HEART DISEASE: ACUTE CORONARY SYNDROMES 275 16 Overview of Acute Coronary Syndromes and Drug Therapy 277 16.1 Introduction 277 16.2 Definitions and General Considerations 277 16.3 Pathophysiology and Drug Targeting 278 16.4 Summary of Chapter Key Points 280 16.5 Self-Assessment Questions 281 References 281 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
17 Anticoagulants, Platelet Inhibitors, and Thrombolytic Agents 283 17.1 Overview 283 17.2 Hemostasis 283 17.3 Anticoagulants 285 17.4 Platelet Inhibitors 295 17.5 Thrombolytic Agents 304 17.6 Summary of Chapter Key Points 307 17.7 Self-Assessment Questions 307 References 308 18 Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction: Principles and Guidelines 310 18.1 Overview 310 18.2 Introduction to Evidence-Based Guidelines 310 18.3 General Principles of Management of UA/NSTEMI 311 18.4 Guideline-Based Recommendations on the Management of UA/NSTEMI 311 18.5 Summary of Chapter Key Points 324 18.6 Self-Assessment Questions 325 References 325 19 Management of ST-Elevation Myocardial Infarction: Principles and Guidelines 327 19.1 Overview 327 19.2 Definition and Epidemiology 327 19.3 Introduction to Recent Guidelines on the Management of STEMI 328 19.4 Principles and Guideline Recommendations for the Management of STEMI 329 19.5 Summary of Chapter Key Points 339 19.6 Self-Assessment Questions 340 References 340 UNIT VI HEART FAILURE 343 20 Overview of Heart Failure and Drug Therapy 345 20.1 Introduction 345 20.2 Definition, Classification, and Epidemiology 345 20.3 Pathophysiology and Drug Targeting 348 20.4 Summary of Chapter Key Points 349 20.5 Self-Assessment Questions 350 References 350 21 Drugs for Heart Failure 352 21.1 Overview 352 21.2 Diuretics for Heart Failure 352 21.3 -Blockers for HF 352 21.4 Inhibitors of the RAAS for HF 353 21.5 Vasodilators for HF 354 21.6 Positive Inotropic Agents for HF 354 21.7 Emerging Drugs for HF 359 21.8 Summary of Chapter Key Points 360 21.9 Self-Assessment Questions 360 References 361 22 Management of Heart Failure: Principles and Guidelines 364 22.1 Overview 364 22.2 Management of Hf-REF 364 22.3 Management of HF-PEF 367 22.4 Management of Acute Heart Failure Syndromes 368 22.5 Summary of Chapter Key Points 372 22.6 Self-Assessment Questions 373 References 374 UNIT Vii CARDIAC ARRHYTHMIAS 375 23 Overview of Cardiac Arrhythmias and Drug Therapy 377 23.1 Introduction 377 23.2 Definition, Classification, and Epidemiology 377 23.3 Pathophysiology and Drug Targeting 380 23.4 Summary of Chapter Key Points 388 23.5 Self-Assessment Questions 389 References 390 24 Drugs for Cardiac Arrhythmias 391 24.1 Overview 391 24.2 Classification of Antiarrhythmic Drugs 391 24.3 Class I Antiarrhythmic Drugs 392 24.4 Class II Antiarrhythmic Drugs 398 24.5 Class III Antiarrhythmic Drugs 399 24.6 Class IV Antiarrhythmic Drugs 404 24.7 Other Antiarrhythmic Drugs 406 24.8 Summary of Chapter Key Points 408 24.9 Self-Assessment Questions 409 References 410 25 Management of Cardiac Arrhythmias: Principles and Guidelines 411 25.1 Overview 411 25.2 General Principles of Management 411 25.3 Management of Supraventricular Arrhythmias 411 25.4 Management of Ventricular Arrhythmias 414 25.5 Summary of Chapter Key Points 421 25.6 Self-Assessment Questions 423 References 424 UNIT Viii ISCHEMIC STROKE 427 26 Overview of Ischemic Stroke and Drug Therapy 429 26.1 Introduction 429 26.2 Definition and Classification of Cerebrovascular Diseases 429 26.3 Definition and Classification of Stroke 429 26.4 Epidemiology of Stroke 430 26.5 Risk Factors of Stroke 432 26.6 Pathophysiology of Ischemic Stroke and Drug Targeting 432 26.7 Summary of Chapter Key Points 434 26.8 Self ]Assessment Questions 434 References 435 27 Drugs for Ischemic Stroke 436 27.1 Overview 436 27.2 Drugs for Primary Prevention of Ischemic Stroke 436 27.3 Drugs for Early Treatment of Acute Ischemic Stroke 438 27.4 Drugs for Neuroprotection 439 27.5 Drugs for Secondary Prevention of Ischemic Stroke 441 27.6 Stem Cell Therapy for Neurorepair 442 27.7 Summary of Chapter Key Points 442 27.8 Self-Assessment Questions 443 References 444 28 Management of Ischemic Stroke: Principles and Guidelines 447 28.1 Overview 447 28.2 Introduction to Stroke Systems of Care 447 28.3 Current AHA/ASA Guidelines on Early Management of Acute Ischemic Stroke 449 28.4 Summary of Chapter Key Points 450 28.5 Self-Assessment Questions 455 References 456 INDEX 457 |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Cardiovascular Diseases |
| General subdivision |
drug therapy. |
| 9 (RLIN) |
16183 |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Case Reports. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Evidence-Based Medicine |
| General subdivision |
methods. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Molecular Medicine |
| General subdivision |
methods. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Online version: |
| Main entry heading |
Li, Yunbo, author. |
| Title |
Cardiovascular diseases |
| Place, publisher, and date of publication |
Hoboken, New Jersey : John Wiley & Sons, Inc., [2015] |
| International Standard Book Number |
9781118889916 |
| Record control number |
(DLC) 2015000334 |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Abstract |
| Uniform Resource Identifier |
<a href="http://repository.fue.edu.eg/xmlui/handle/123456789/1794">http://repository.fue.edu.eg/xmlui/handle/123456789/1794</a> |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
orignew |
| d |
1 |
| e |
ecip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |